keyword
MENU ▼
Read by QxMD icon Read
search

survival improvement in patients with pancreatic cancer

keyword
https://www.readbyqxmd.com/read/28105537/procedures-and-recommended-times-in-the-care-process-of-the-patient-with-pancreatic-cancer-pan-time-consensus-between-scientific-societies
#1
R Vera, A Ferrández, C J Ferrer, C Flores, C Joaquín, S López, T Martín, E Martín, M Marzo, A Sarrión, E Vaquero, A Zapatero, J Aparicio
PURPOSE: Pancreatic cancer (PC) is a disease with bad prognosis. It is usually diagnosed at advanced stages and its treatment is complex. The aim of this consensus document was to provide recommendations by experts that would ameliorate PC diagnosis, reduce the time to treatment, and optimize PC management by interdisciplinary teams. METHODS: As a consensus method, we followed the modified Delphi methodology. A scientific committee of experts provided 40 statements that were submitted in two rounds to a panel of 87 specialists of 12 scientific societies...
January 19, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28104298/kr%C3%A3-pple-like-factor-10-regulates-radio-sensitivity-of-pancreatic-cancer-via-uv-radiation-resistance-associated-gene
#2
Vincent Hung-Shu Chang, Yi-Chih Tsai, Ya-Li Tsai, Shu-Ling Peng, Su-Liang Chen, Tsung Ming Chang, Winston Chun-Yuan Yu, Hui-Ju Ch'ang
BACKGROUND AND PURPOSE: Krüpple-like factor 10 (Klf10), an early response gene of TGFβ, was reported to be a prognostic biomarker for pancreatic cancer survival. The role of Klf10 in predicting tumor response to cancer treatment is unknown. MATERIALS AND METHODS: Genetically manipulated MiaPaCa and Panc-1 cells were established to evaluate clonogenic survival, autophagy, apoptosis and DNA repair after radiation. The interaction between Klf10 and UV radiation resistance-associated gene (UVRAG) was demonstrated by ChiP-PCR and luciferase reporter assay...
January 16, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28103577/association-of-rab5-overexpression-in-pancreatic-cancer-with-cancer-progression-and-poor-prognosis-via-e-cadherin-suppression
#3
Takamichi Igarashi, Kenichiro Araki, Takehiko Yokobori, Bolag Altan, Takahiro Yamanaka, Norihiro Ishii, Mariko Tsukagoshi, Akira Watanabe, Norio Kubo, Tadashi Handa, Yasuo Hosouchi, Masahiko Nishiyama, Tetsunari Oyama, Ken Shirabe, Hiroyuki Kuwano
Pancreatic cancer is a common type of cancer with poor prognosis worldwide. Postoperative survival depends on the existence of metastasis. Elucidation of the mechanism underlying cancer progression is important to improve prognosis. The RAS-associated protein RAB5 activates intracellular membrane trafficking, and RAB5 expression is correlated to progression and epithelial mesenchymal transition in various cancers.The expression of RAB5 and E-cadherin in 111 pancreatic cancer samples was investigated by immunohistochemical staining, and the relationship among RAB5 expression, clinicopathological factors, and E-cadherin expression was assessed...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28099921/stiehopus-japonieus-acidic-mucopolysaccharide-inhibits-the-proliferation-of-pancreatic-cancer-sw1990-cells-through-hippo-yap-pathway
#4
Xiaoyu Li, Yi Liu, Cuiping Zhang, Qinghui Niu, Hui Wang, Cong Che, Man Xie, Bin Zhou, Yonghong Xu, Qi Zhang, Jun Wu, Zibin Tian
Previous studies have indicated that stiehopus japonieus acidic mucopolysaccharide (SJAMP) could inhibit the proliferation of pancreatic cancer cell SW1990. However, the mechanism remains unclear. In our study, YAP expression was identified by immunohistochemistry and quantitative Real-time PCR from 45 pairs of human pancreatic ductal adenocarcinoma (PDAC) tissues and their adjacent non-tumor samples. We found that the YAP expression was associated with the histological differentiation degree, and negatively correlated with pancreatic cancer patients' survival...
January 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28099248/overexpression-of-ykl-40-predicts-poor-prognosis-in-patients-undergoing-curative-resection-of-pancreatic-cancer
#5
Hai-Tao Chen, Jian-Ming Zheng, Yong-Zhen Zhang, Ming Yang, Yu-Ling Wang, Xiao-Hua Man, Yan Chen, Quan-Cai Cai, Zhao-Shen Li
OBJECTIVES: The aim of this study was to determine the prognostic value of YKL-40 expression in patients undergoing curative resection of pancreatic cancer. METHODS: This cohort study included 234 consecutive patients with pancreatic ductal adenocarcinoma who underwent curative resection. Surgical specimens were immunohistochemically assessed for YKL-40 expression. Kaplan-Meier method and Cox regression were used to evaluate the prognostic impact of YKL-40 expression...
January 18, 2017: Pancreas
https://www.readbyqxmd.com/read/28093284/pancreatic-cancer-stroma-and-its-current-and-emerging-targeted-therapies
#6
Janaiah Kota, Julie Hancock, Jason Kwon, Murray Korc
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal human malignancies with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is a major obstacle for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Targeting stroma is considered as a potential therapeutic strategy to improve anti-cancer drug efficacy and patient survival. Although numerous stromal depletion therapies have reached the clinic, they add little to overall survival and are often associated with toxicity...
January 14, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28081546/advanced-pancreatic-adenocarcinoma-outcomes-with-transition-from-devolved-to-centralised-care-in-a-regional-cancer-centre
#7
Olusola O Faluyi, Joanna L Connor, Madhuchanda Chatterjee, Carl Ikin, Helen Wong, Daniel H Palmer
BACKGROUND: Previous observations suggest suboptimal 'real world' survival outcomes for advanced pancreatic adenocarcinoma. We hypothesized that centralisation of advanced pancreatic adenocarcinoma management would improve chemotherapy treatment and survival from the disease. METHODS: The data was prospectively collected on all cases of advanced pancreatic adenocarcinoma reviewed through Clatterbridge Cancer Centre according to two groups; 1 October 2009-31st Dec 2010 (devolved care) or 1 January 2013-31 March 2014 (centralised care)...
January 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28079594/impact-of-concurrent-medication-use-on-pancreatic-cancer-survival-seer-medicare-analysis
#8
Muhammad S Beg, Arjun Gupta, David Sher, Sadia Ali, Saad Khan, Ang Gao, Tyler Stewart, Chul Ahn, Jarett Berry, Eric M Mortensen
OBJECTIVES: Preclinical studies have suggested that non-antineoplastic medication use may impact pancreatic cancer biology. We examined the association of several medication classes on pancreatic cancer survival in a large medical claims database. MATERIALS AND METHODS: Histologically confirmed pancreatic adenocarcinoma diagnosed between 2006 and 2009 were analyzed from the Surveillance, Epidemiology, and End Results-Medicare database with available part D data...
January 10, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28078125/changing-paradigm-in-pancreatic-cancer-from-adjuvant-to-neoadjuvant-chemoradiation
#9
Justin D Anderson, Wen Wan, Brian J Kaplan, Jennifer Myers, Emma C Fields
BACKGROUND: Historically, management of pancreatic cancer has been determined based on whether the tumor was amenable to resection and all patients deemed resectable received curative intent surgery followed by adjuvant therapy with chemotherapy (CT) ± RT. However, patients who undergo resection with microscopic (R1) positive margins have inferior rates of survival. The purpose of this study is to identify patients who have undergone pancreatectomy for pancreatic cancer, determine the surgical margins, types of adjuvant therapies given and patterns of failure...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28072706/a-randomized-multicenter-phase-iii-study-of-gemcitabine-combined-with-capecitabine-versus-gemcitabine-alone-as-first-line-chemotherapy-for-advanced-pancreatic-cancer-in-south-korea
#10
Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Ho Gak Kim, Myung Hwan Noh, Sang Hyub Lee, Yong-Tae Kim, Hyo Jung Kim, Chang Duck Kim, Dong Ki Lee, Kwang Bum Cho, Chang Min Cho, Jong Ho Moon, Dong Uk Kim, Dae Hwan Kang, Young Koog Cheon, Ho Soon Choi, Tae Hyeon Kim, Jae Kwang Kim, Jieun Moon, Hye Jung Shin, Si Young Song
BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. METHODS: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660 mg/m plus Gem 1000 mg/m by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion weekly for 3 weeks every 4 weeks)...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28070725/type-of-resection-whipple-vs-distal-does-not-affect-the-national-failure-to-provide-post-resection-adjuvant-chemotherapy-in-localized-pancreatic-cancer
#11
John R Bergquist, Tommy Ivanics, Christopher R Shubert, Elizabeth B Habermann, Rory L Smoot, Michael L Kendrick, David M Nagorney, Michael B Farnell, Mark J Truty
INTRODUCTION: Adjuvant chemotherapy improves survival after curative intent resection for localized pancreatic adenocarcinoma (PDAC). Given the differences in perioperative morbidity, we hypothesized that patients undergoing distal partial pancreatectomy (DPP) would receive adjuvant therapy more often those undergoing pancreatoduodenectomy (PD). METHODS: The National Cancer Data Base (2004-2012) identified patients with localized PDAC undergoing DPP and PD, excluding neoadjuvant cases, and factors associated with receipt of adjuvant therapy were identified...
January 9, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28056913/prognostic-relevance-of-lactate-dehydrogenase-in-advanced-pancreatic-ductal-adenocarcinoma-patients
#12
Yuanyuan Xiao, Wen Chen, Zhihui Xie, Zhenyi Shao, Hua Xie, Guoyou Qin, Naiqing Zhao
BACKGROUND: The prognostic role of pretreatment serum lactate dehydronegase (LDH) has been well established in many malignant tumors, albeit it remains under-discussed in pancreatic cancer. In the present study, we aimed to assess the association between baseline LDH levels and overall survival (OS) in advanced pancreatic ductal adenocarcinoma (PDAC) patients who did and did not receive subsequent chemotherapy. METHODS: In total, 135 retrospectively determined patients with locally advanced or metastatic PDAC, who were diagnosed between 2012 and 2013, were analyzed...
January 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28056391/proton-pump-inhibitors-on-pancreatic-cancer-risk-and-survival
#13
Malcolm D Kearns, Ben Boursi, Yu-Xiao Yang
BACKGROUND: Hypergastrinemia may promote the development and progression of pancreatic cancer. Proton pump inhibitor (PPI) therapy is known to cause hypergastrinemia. We sought to determine the association between PPI therapy and the risk of developing pancreatic cancer as well as survival following pancreatic cancer diagnosis. METHODS: We conducted a nested case-control study and a retrospective cohort study in The Health Improvement Network (THIN), a medical records database representative of the UK population...
January 2, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28047421/mo-de-207b-03-improved-cancer-classification-using-patient-specific-biological-pathway-information-via-gene-expression-data
#14
M Young, D Craft
PURPOSE: To develop an efficient, pathway-based classification system using network biology statistics to assist in patient-specific response predictions to radiation and drug therapies across multiple cancer types. METHODS: We developed PICS (Pathway Informed Classification System), a novel two-step cancer classification algorithm. In PICS, a matrix m of mRNA expression values for a patient cohort is collapsed into a matrix p of biological pathways. The entries of p, which we term pathway scores, are obtained from either principal component analysis (PCA), normal tissue centroid (NTC), or gene expression deviation (GED)...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28044263/five-fraction-stereotactic-body-radiation-therapy-sbrt-and-chemotherapy-for-the-local-management-of-metastatic-pancreatic-cancer
#15
Jonathan W Lischalk, Aidan Burke, Jessica Chew, Christen Elledge, Marie Gurka, John Marshall, Michael Pishvaian, Sean Collins, Keith Unger
BACKGROUND: The majority of patients with pancreatic cancer are diagnosed with metastatic disease at presentation. Nevertheless, local progression is responsible for up to 30% of deaths and can lead to significant morbidity. As a consequence, further exploration of effective methods of local control and palliation is essential. Stereotactic body radiation therapy (SBRT) is a widely utilized technique for the treatment of localized pancreatic cancer. Here, we report our experience with SBRT and chemotherapy for the local treatment of the metastatic patient population...
January 3, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28040693/influence-of-statins-and-cholesterol-on-mortality-among-patients-with-pancreatic-cancer
#16
Brian Z Huang, Jonathan I Chang, Erica Li, Anny H Xiang, Bechien U Wu
BACKGROUND: Recent studies have suggested associations between statins and enhanced survival among patients with pancreatic ductal adenocarcinoma (PDAC). However, the relationship between statins, cholesterol, and survival remains unclear. METHODS: We conducted a retrospective cohort study on 2142 PDAC patients in a regional integrated healthcare system from 2006 to 2014. Electronic pharmacy records were used to abstract information on the type, length, and dosage of statin exposures starting in the year prior to diagnosis...
May 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28028360/dilemma-of-first-line-regimens-in-metastatic-pancreatic-adenocarcinoma
#17
REVIEW
Marwan Ghosn, Tony Ibrahim, Tarek Assi, Elie El Rassy, Hampig Raphael Kourie, Joseph Kattan
Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer (mPC) remains cytotoxic chemotherapy. In 2016, more than 40 years after the introduction of gemcitabine in the management of mPC, the best choice for first-line treatment has not yet been fully elucidated. Two main strategies have been adopted to enhance treatment efficacy...
December 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28025817/cost-effectiveness-of-metal-stents-in-relieving-obstructive-jaundice-in-patients-with-pancreatic-cancer
#18
J M Martinez, A Anene, T G K Bentley, M J Cangelosi, L M Meckley, J D Ortendahl, A J Montero
BACKGROUND: ASGE and ESGE guidelines recommend endoscopic metal stent placement for pancreatic carcinoma patients with biliary obstruction, and whose estimated life expectancy is greater than 6 months. Because median overall survival (OS) of metastatic pancreatic adenocarcinoma until recently has been less than 6 months, plastic biliary stents were preferentially placed rather than metal due to the greater upfront cost of the latter. Recent advances in the treatment of metastatic pancreatic cancer have extended median OS beyond the 6-month range...
December 27, 2016: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28010955/three-year-and-five-year-outcomes-of-surgical-resection-for-pancreatic-ductal-adenocarcinoma-long-term-experiences-in-one-medical-center
#19
Chih-Po Hsu, Jun-Te Hsu, Chien-Hung Liao, Shih-Ching Kang, Being-Chuan Lin, Yu-Pao Hsu, Chun-Nan Yeh, Ta-Sen Yeh, Tsann-Long Hwang
OBJECTIVE: Pancreatic ductal adenocarcinoma is one of the most malignant types of cancer. This study evaluated the 3-year and 5-year surgical outcomes associated with the cancer and determined whether statistically identified factors can be used to predict survival. METHODS: This retrospective review was conducted from 1995 to 2010. Patients who had resectable pancreatic ductal adenocarcinoma and received surgical treatment were included. Cases of hospital mortality were excluded...
December 20, 2016: Asian Journal of Surgery
https://www.readbyqxmd.com/read/27999205/muty-homolog-myh-inhibition-reduces-pancreatic-cancer-cell-growth-and-increases-chemosensitivity
#20
George Sharbeen, Janet Youkhana, Amanda Mawson, Joshua McCarroll, Andrea Nunez, Andrew Biankin, Amber Johns, David Goldstein, Phoebe Phillips
Patients with pancreatic ductal adenocarcinoma (PC) have a poor prognosis due to metastases and chemoresistance. PC is characterized by extensive fibrosis, which creates a hypoxic microenvironment, and leads to increased chemoresistance and intracellular oxidative stress. Thus, proteins that protect against oxidative stress are potential therapeutic targets for PC. A key protein that maintains genomic integrity against oxidative damage is MutY-Homolog (MYH). No prior studies have investigated the function of MYH in PC cells...
December 16, 2016: Oncotarget
keyword
keyword
66462
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"